Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 37

References for PMC Articles for PubMed (Select 20843305)

1.

Differences in tumor type in low-stage versus high-stage ovarian carcinomas.

Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency, Vancouver BC.

Int J Gynecol Pathol. 2010 May;29(3):203-11. doi: 10.1097/PGP.0b013e3181c042b6.

PMID:
20407318
2.

BRCA1 represses amphiregulin gene expression.

Lamber EP, Horwitz AA, Parvin JD.

Cancer Res. 2010 Feb 1;70(3):996-1005. doi: 10.1158/0008-5472.CAN-09-2842. Epub 2010 Jan 26.

3.

Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations.

Bellacosa A, Godwin AK, Peri S, Devarajan K, Caretti E, Vanderveer L, Bove B, Slater C, Zhou Y, Daly M, Howard S, Campbell KS, Nicolas E, Yeung AT, Clapper ML, Crowell JA, Lynch HT, Ross E, Kopelovich L, Knudson AG.

Cancer Prev Res (Phila). 2010 Jan;3(1):48-61. doi: 10.1158/1940-6207.CAPR-09-0078.

4.

MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.

Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, Huntsman D, van de Rijn M, Gilks CB.

PLoS One. 2009 Oct 2;4(10):e7314. doi: 10.1371/journal.pone.0007314.

5.

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Vang R, Shih IeM, Kurman RJ.

Adv Anat Pathol. 2009 Sep;16(5):267-82. doi: 10.1097/PAP.0b013e3181b4fffa. Review.

6.

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS.

N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24.

7.

Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis.

Holland AJ, Cleveland DW.

Nat Rev Mol Cell Biol. 2009 Jul;10(7):478-87. doi: 10.1038/nrm2718. Review.

8.

Cancer statistics, 2009.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ.

CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.

9.

Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications.

Pradhan M, Davidson B, Tropé CG, Danielsen HE, Abeler VM, Risberg B.

Virchows Arch. 2009 Jun;454(6):677-83. doi: 10.1007/s00428-009-0778-y. Epub 2009 May 8.

PMID:
19421773
10.

Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment.

Venkitaraman AR.

Annu Rev Pathol. 2009;4:461-87. doi: 10.1146/annurev.pathol.3.121806.151422. Review.

PMID:
18954285
11.

Critical molecular abnormalities in high-grade serous carcinoma of the ovary.

Köbel M, Huntsman D, Gilks CB.

Expert Rev Mol Med. 2008 Aug 1;10:e22. doi: 10.1017/S146239940800077X. Review.

PMID:
18671886
12.

Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma.

Tone AA, Begley H, Sharma M, Murphy J, Rosen B, Brown TJ, Shaw PA.

Clin Cancer Res. 2008 Jul 1;14(13):4067-78. doi: 10.1158/1078-0432.CCR-07-4959.

13.

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.

Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG.

BMC Cancer. 2008 Jan 22;8:17. doi: 10.1186/1471-2407-8-17.

14.

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability.

Gudmundsdottir K, Ashworth A.

Oncogene. 2006 Sep 25;25(43):5864-74. Review.

PMID:
16998501
15.

Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas.

Pradhan M, Abeler VM, Danielsen HE, Tropé CG, Risberg BA.

Mod Pathol. 2006 Sep;19(9):1227-35. Epub 2006 May 26.

16.

BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.

Chiang JW, Karlan BY, Cass L, Baldwin RL.

Gynecol Oncol. 2006 Jun;101(3):403-10. Epub 2005 Dec 19.

PMID:
16360812
17.

Targeting the DNA repair defect of BRCA tumours.

Turner N, Tutt A, Ashworth A.

Curr Opin Pharmacol. 2005 Aug;5(4):388-93. Review.

PMID:
15955736
18.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A.

Nature. 2005 Apr 14;434(7035):917-21.

19.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T.

Nature. 2005 Apr 14;434(7035):913-7. Erratum in: Nature. 2007 May 17;447(7142):346.

20.

Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles.

Subramanian S, West RB, Corless CL, Ou W, Rubin BP, Chu KM, Leung SY, Yuen ST, Zhu S, Hernandez-Boussard T, Montgomery K, Nielsen TO, Patel RM, Goldblum JR, Heinrich MC, Fletcher JA, van de Rijn M.

Oncogene. 2004 Oct 14;23(47):7780-90.

PMID:
15326474
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk